scholarly journals Chemotherapy-Induced First Bite Syndrome: A Case Report in a Patient With Hodgkin Lymphoma

2019 ◽  
Vol 98 (5) ◽  
pp. E30-E31 ◽  
Author(s):  
Carla V. Valenzuela ◽  
Nancy L. Bartlett ◽  
Joseph P. Bradley

Vinca alkaloids are known to cause bilateral jaw pain that occurs once during the chemotherapy course. We report a patient with first bite syndrome (FBS) during active treatment with chemotherapy. A patient with Hodgkin lymphoma presented with unilateral jaw pain after beginning his chemotherapy regimen. Pain was worse with the first bite of each meal and dissipated over subsequent bites. Workup was negative for any lesions in the parotid, parapharyngeal space, or infratemporal fossa. Pain was timed closely with chemotherapy administration and would improve prior to next cycle. A trial of botulinum chemodenervation failed to completely relieve symptoms. The patient noted resolution of symptoms after the completion of chemotherapy. We report a case of FBS, which may represent the jaw pain seen commonly with administration of vinca alkaloids. There appears to be a correlation between onset and duration of first bite symptoms with chemotherapy administration.

2020 ◽  
Vol 12 (1) ◽  
pp. 15-18
Author(s):  
Beatrice Tonin ◽  
Davide Geat ◽  
Giampiero Girolomoni

AbstractFlagellate dermatitis represents a unique cutaneous eruption associated with several causes, including treatment with certain chemotherapeutic agents, ingestion of toxins and rheumatologic conditions like adult-onset Still’s disease and dermatomyositis. We present the case of a 35-year-old woman with stage IIA Hodgkin lymphoma who was treated with the ABVD chemotherapy regimen (doxorubicin, bleomycin, vinblastine and dacarbazine). During the third cycle of chemotherapy, she developed multiple linear erythematous macules and hyperpigmentation in a striking flagellate-like pattern localized on the upper chest, submammary folds, neck and upper part of the back. The lesions resolved completely within three months after the withdrawal of bleomycin. Clinicians should be aware of this distinctive cutaneous toxicity in patients receiving bleomycin combination chemotherapy.


1998 ◽  
Vol 91 (8) ◽  
pp. 817-820
Author(s):  
Sanson HAN ◽  
Hiroyuki KITAMURA ◽  
Shin-ichi TAKAGITA ◽  
Toshiki MAETANI ◽  
Yuka IWAHASHI ◽  
...  

2021 ◽  
Vol 16 (5) ◽  
pp. 1099-1102
Author(s):  
Meryeme Chihabeddine ◽  
Asmaa Naim ◽  
Mariam Kassimi ◽  
Jihane Habi ◽  
Mohamed Mahi ◽  
...  

Author(s):  
Miguel García-Grimshaw ◽  
Amado Jiménez-Ruiz ◽  
José Luis Ruiz-Sandoval ◽  
Carlos Cantú-Brito ◽  
Erwin Chiquete

2020 ◽  
Vol 14 (1) ◽  
Author(s):  
Eyal Meir ◽  
Chovav Handler ◽  
Uri Kaplan ◽  
Doron Kopelman ◽  
Ossama A. Hatoum

Abstract Introduction Primary lymphoma of the colon is exceedingly rare and comprises 0.2–1% of all colon tumors. The most common subtype of lymphoma in the colon is non-Hodgkin lymphoma. Symptoms are often nonspecific, and treatment varies between chemotherapy alone and a combination of surgery and chemotherapy. Case presentation We describe a case of a Ashkenazi Jew patient who presented in the typical way that carcinoma of the colon might present but turned out to have a very rare type of tumor in both its histology and its location. Conclusion There was apparent discordance between the relative bulkiness and gross appearance of the tumor with the unrevealing result of the biopsies, demanding a high level of suspicion as to the actual presence and possible type of such a tumor in the future.


2013 ◽  
Vol 3 (1) ◽  
Author(s):  
Matthew M DeNicola ◽  
Jonathan W Said ◽  
Sheeja T Pullarkat

Sign in / Sign up

Export Citation Format

Share Document